Lilly refutes reports of insulin shortage

March 24, 2020

Eli Lilly have announced that it does not anticipate shortages for any of its medicines, including all forms of insulin.

According to Lilly, it has monitored its supply chain for potential impact to the supply of its medicines since the initial outbreak. Its insulin manufacturing sites in the U.S. and Europe remain operational, with increased precautions in place to protect the supply of medicine.

Lilly says that U.S. pharmacies that don't have its medicines in stock can order from wholesalers, and generally they can be delivered in 1 to 2 days. Lilly has received a few reports of U.S. pharmacies stating that insulin orders are not being fulfilled due to "manufacturer backorder." Lilly has informed wholesalers and others in the supply chain that none of its products are on backorder, including insulin. The drugmaker suggests that patients should ask their pharmacist to secure an order from their wholesaler.

Read the full Eli Lilly statement